Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals
November 06, 2014 at 09:58 AM EST
In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $8.00 price target on Ariad ...